Sign In to Follow Application
View All Documents & Correspondence

Composition And Method For Controlling Release Of Active Ingredient

Abstract: A coating composition based on sodium alginate is designed to release the active ingredient of pharmaceutical substances veterinary substances nutraceutical products and food and confectionery products after a pre determined lag period and a method of preparing the coating composition is also provided.

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #
Filing Date
28 August 2013
Publication Number
35/2014
Publication Type
INA
Invention Field
PHARMACEUTICALS
Status
Email
Parent Application

Applicants

IDEAL CURES PVT. LTD
A 223 to 229 2nd Floor Virwani Industrial Estate Off Western Express Highway Goregaon (East) IN 400063 Mumbai India

Inventors

1. PAREEK Suresh
IDEAL CURES PVT. LTD |A 223 to 229 1st Floor Virwani Industrial Estate Off Western Express Highway Goregaon (EAST) IN 400063 Mumbai
2. RAJSHARAD Chetan
IDEAL CURES PVT. LTD |A 223 to 229 1st Floor Virwani Industrial Estate Off Western Express Highway Goregaon (EAST) IN 400063 Mumbai
3. LUINI Dario
IDEAL CURES PVT. LTD |A 223 to 229 1st Floor Virwani Industrial Estate Off Western Express Highway Goregaon (EAST) IN 400063 Mumbai

Specification

COMPOSITION AND METHOD FOR CONTROLLING RELEASE OF ACTIVE INGREDIENT
FIELD OFTHE INVENTION
The present invention relates t o development of film coating compositions designed t o
release active ingredient of pharmaceutical substances, veterinary substrates, nutraceutical
products, and food and confectionery products over a predetermined period and a process
of producing such a composition.
BACKGROUND OFTHE INVENTION:
Currently, most commercially available edible film coatings comprise a combination of
synthetic cellulosic polymer such as hydroxyl-propyl-methyl-cellulose (HPMC), a film former
such as ethylcellulose, methylcellulose, polyvinylpyrrolidone, and polydextrose together
with other ingredients including fillers, for example, lactose or maltodextrin; plasticizers,
such as polyethylene glycols, dibutylsebacate, and triethyl citrate; surfactants; and often
coloring materials such as a food dye or pigment, including opacifiers such as titanium
dioxide and the like. These coatings are usually used for immediate release of a given active
ingredient.
Most of the commercially available film coating compositions are used either for immediate
release where the coated substrate disintegrates quickly in stomach and releases the active
component in the acidic environment of the stomach or designed for enteric release where
the substrate is coated with a pH dependent polymer so that the coating remains intact in
acidic pH of stomach but dissolves quickly as soon as it confronts alkaline pH of the intestine
t o release the active ingredient. The release of the active ingredient from such pH
dependent polymeric film takes anything from 2 hours t o 4 hours depending on the
physiology of the patient, the solubility of the polymer at different pH and the kind of food
available in the stomach.
US Patent 4,792,452 describes one such controlled release composition where the active
ingredient is released at a controlled rate regardless of the pH of the environment. The
composition comprises a pH dependent polymer particularly sodium salt of alginic acid, a pH
dependent hydrocarbon gelling agent such as hydroxypropyl methyl cellulose along with
other pharmaceutical excipients.
WO9813029 (also published as US6183780) describes an oral delayed immediate release
formulation that comprises a non swellable core containing the active ingredient and is
surrounded by a coating. The active ingredient is released by the rupture of the coating
upon exposure to the gastrointestinal fluids. The coating composition comprises a polymeric
material such as ethyl cellulose, a water soluble plasticizing agent, and a brittleness inducing
agent.
WO2008110577 (US 2010028426) discloses a time specific delayed/pulsatile release dosage
forms that releases the active ingredient after a predetermined lag period independently of
the physiological pH variations that occur in the gastrointestinal tract. The dosage form
comprises a core with active ingredient, a sealing layer and an outer coating layer. Both the
sealing layer and coating layer contain atleast one polymer that exhibits pH independent
water solubility. The polymers preferred for the composition include alkylcellulosic
polymers.
WO02076429 discloses a sustained release drug delivery composition comprising about 20-
40% of sodium alginate, about 4-12% of propylene glycol alginate, and about 40-80% of a
pharmaceutical medicament. The invention aims at providing a composition which provides
a dissolution rate of about 20% of drug within 2 hrs at an acidic pH, and the rest of 80% of
the drug is released within at least 10 hrs at alkaline or neutral pH.
There are several products that must be consumed after food and if consumed before food,
the efficacy of the active ingredient is lost or not fully realized due to exposure to very low
pH in the empty stomach. There are certain coating compositions that provide sustained
release formulation, wherein the dose is provided t o obtain a sustained release effect.
Sustained release effect releases the active substance at regular time interval rather than all
together, which may be desired at certain points of time.
Hence, though there are several types of coating compositions in prior art, there is still a
need of a coating composition whereby, an active ingredient may be programmed t o be
released after a pre-determined lag period.
OBJECT OF INVENTION
An object of the invention is to provide a coating composition, which releases the active
ingredient after a pre-determined lag period,
Another object of the invention is to provide a method for preparing the coating
composition of the present invention.
SUMMARY OF THE INVENTION:
The invention provides a coating composition based on sodium alginate, which composition
is designed t o release the active ingredient after a pre-determined lag period.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides a coating composition based on sodium alginate as film
forming polymer and is designed such that the active ingredient is released after a
predetermined lag period.
The coating composition of the present invention essentially comprises a pH independent
polymer, a plasticizer, a detackifier. It also includes other additives such as a preservative,
flavoring agent, opacifiers, fillers/diluents, and coloring agents.
These and other objects of the invention are achieved by developing a composition that
employs sodium alginate as film forming polymer in an amount from 25 to 85%w/w,
together with a plasticizer, detackifier, preservative and other additives.
Sodium Alginate is polymer soluble in aqueous solutions with pH greater than 3.0. In
aqueous acidic solutions with pH less than 3, it is poorly soluble. Thus, sodium alginate is a
pH independent polymer (like enteric coating polymers which are completely insoluble in
acidic pH but dissolve quickly in alkaline pH). It has been found that when used in a coating
composition, the coating composition remains stable at highly acidic pH of empty stomach
(the pH of empty stomach varies from 1.5 to 2.5 whereas the pH of the fed stomach varies
from 2.0 to 4.5 depending on the nature of food and the amount of water taken along with
food).
Sodium alginate is a sodium salt of alginic acid. Alginic acid extracted from various species of
deep-sea weed like Phaeophyceae. Sodium alginate is a polysaccharide, like starch and
cellulose. It is composed of several building units (typically 100-3000) linked together in a
flexible chain. Long molecules constructed from identical or nearly identical building units
are called polymers, while the building units themselves are called monomers. Polymers of
natural origin are commonly called biopolymers.
Sodium alginate is built upon the basis of two sugars, which are both uronates, the salts of
mannuronic and guluronic acid. When producing alginates, uronic acid is converted into the
salt-form mannuronate (M) and guluronate (G).
Generally, Sodium alginate in the pharmaceutical field is used as a stabilizing agent,
suspending agent, tablet and capsule disintegrant, tablet binder and viscosity increasing
agent.
Sodium alginate occurs as an odorless and tasteless, white to pale yellowish-brown colored
powder. A 1% w/v aqueous solution has a pH of about 7.2. It is practically insoluble in
ethanol, ether, chloroform and ethanol/water mixtures in which the ethanol content is
greater than 30%. It is practically insoluble in other organic solvents and aqueous acidic
solutions in which pH is less than 3. It is slowly soluble in water, forming a viscous colloidal
solution. Various grades of sodium alginate are commercially available that yield aqueous
solutions of varying viscosity. A 1% w/w aqueous solution, at 20° C, has a viscosity of 20-400
mPas (20-400 cP). Viscosity may vary depending upon concentration, pH, temperature or
the presence of metal ions. Above pH 10, viscosity decreases.
Sodium alginate has been used in tablet formulations, both a binder and disintegrant; it has
also been used as a diluents in capsule formulations. In topical formulations, Sodium
alginate has been widely used as a thickening and suspending agent in a variety of pastes,
creams and gels and as a stabilizing agent for oil-in-water emulsions. Sodium alginate
solutions are susceptible on storage to microbial spoilage, which may affect solution
viscosity. Heating sodium alginate solutions t o temperatures above 70°C, causes
depolymerization with a loss in viscosity. Autoclaving solutions of sodium alginate may also
cause a decrease in viscosity depending upon the nature of any other substances present.
Gamma irradiation should not be used to sterilize sodium alginate solutions since this
process severely reduces solution viscosity.
Viscosity of Sodium- alginate used in examples are lower as well as higher i.e. 10 cps more
preferably 5-lOcps and higher grade of 15 t o 20cps.
Sodium alginate is generally less susceptible to microbial attack. However, even if the issue
of microbial attack arises, it may be prevented by adding appropriate preservatives to the
composition. Sodium alginate has been used in the art as a film forming polymer. However,
it has met with limited success. At best, sodium alginate has been used for immediate
release. However, the inventors have found that it is possible to achieve disintegration of a
tablet coating after a pre-determined time lag; whereby the active ingredient is released.
The lag-time or predetermined lag time referred is the period during which the drug
substance is held captive and protected by the coating. Thereafter, the coating disintegrates
and releases the drug into gastric media, the desired lag-time may be in the range of 20-120
minutes.
The amount of pH independent polymer used in the composition of the present invention
may be in the range of 25% w/w t o 85% w/w of the composition.
The plasticizer used in the composition may be selected from the group consisting of
polyethylene glycol, propylene glycol, glycerin, triacetin, triethyl citrate, diethyl phthalate,
dibutyl phthalate, liquid paraffin, castor oil, triglycerides, coconut oil etc.
The amount of plasticizer may vary from 3% w/w to 15% w/w of the composition.
The present invention includes a detackifier which helps in reducing the tackiness so that
the composition has lesser tendency t o agglomerate. The detackifier may be selected any of
talc, stearic acid, stearates of calcium, magnesium or zinc, kaolin, Glyceryl mono stearate.
The amount of detackifier may vary from 1% w/w to 35% w/w of the composition.
The composition of the present invention would optionally include additives such as
preservative, pigments (coloring agent), opacifier, diluents, lubricant, sweetener and
flavoring agent.
A preservative selected from any of sorbic acid, potassium sorbate, benzoic acid, sodium
benzoate or esters of hydroxybenzoic acid, parabensetc, may be employed in the
composition to avoid attack by fungi/bacteria.
The amount of preservative may be in the range of 0.1% w/w t o 2% w/w of the
composition.
The colouring agent or the pigment may be selected from any colors and lakes approved by
the FD & C. A non limiting list of pigments that may be used in the composition of present
invention includes, iron oxide colors, Lake colours, natural colours, Candurin™ colors and
the like.
Opacifiers of the present invention may be selected from the group comprising titanium
dioxide, zinc oxide, calcium carbonate, magnesium oxide and the like.
Diluent used in the composition may be any of Tri basic calcium phosphate, Lactose, Microcrystalline
cellulose, calcium phosphate and the like.
Lubricants used in the composition may be any of magnesium stearate, calcium stearate,
zinc stearate, stearic acid, mineral oil, and combinations thereof.
Sweeteners may be such as comprising glucose, fructose, sorbitol, aspartame, glycerol,
saccharin, xylitol and the like.
Flavoring agents of the present invention may be selected from the group comprising
powder, liquid, encapsulated flavors either natural or synthetic origin.
Substrates of the present invention comprise but are not limited to pharmaceutical
materials, nutritional supplements, food, confectionery forms.
The coating composition of the present invention comprises the pH independent polymer,
preferably sodium alginate in the range of more preferably 25 to 85% w/w, plasticizer in the
range of 3-15 % w/w, preferably 4-12% w/w, a detackifier in the range of 1-35% w/w, a
preservative in the range of 0.1-2% w/w and optionally a pigment in the range of 0.1-35%
w/w, an opacifier in the range of 0.1-30 %w/w and other excipients in the range of 0.1-20 %
w/w.
The invention has also found that the content of sodium alginate and coating weight gain on
the tablet is related to the lag time for disintegration of the coating. In other wordsby
increasing the coating weight gain on the tablet, the lag-period may be varied. 'Weight gain'
as used herein means theamount of coating applied to the. The release of the active
ingredient may be favorably altered by a pre-determined lag period, by varying the weight
gain from 5to 20%.
The lag period may be determined based on the amount of sodium alginate employed
and/or the weight gain in the coating process. Upon testing disintegration time at pH 1.2 the
coated tablet remained intact from about 30 minutes to 120 minutes at coating weight gain
varying from 4% t o 16% w/w respectively. Further size and shape of the oral substrate like
tablet/soft-gel capsule and physical properties of active ingredient may lead to variation in
disintegration time.
Some non-limiting examples of the same is presented below:
TABLE 1
The composition of the invention may be manufactured either as a dry ready to use powder
which may be constituted at the user's end or may be developed as an aqueous
composition.
Tablet Cores are manufactured in standard manner.The active ingredient and optionally
other ingredients are first blended in a mixer, and then the solution or suspension of binder
is sprayed onto this mix in a granulator. For example, fluidized bed granulators can be used
for this operation. An alternative process can be t o use a conventional or high shear mixer
to achieve granulation to obtain granules. Granules once dried can be mixed with the other
excipients, especially with the lubricant, but also with glidants and any other excipient
suitable t o improve processing. The mixture of granules (preferably with lubricant), and
optionally glidant is pressed into tablets. Alternatively, tablets containing the active
ingredient can be obtained by standard techniques, and are hereinafter referred as tablet
cores.These tablet cores are then coated with the coating composition of the invention to
achieve a desired time release of the active ingredient.
The relative amounts of ingredients in the coating are preferably as follows. The proportion
of pH independent polymer such as sodium alginate in the coating may vary between
25to85.0% of the coating dry weight. The proportion of plasticizer in the coating may vary
between 3 to 15% of the coating dry weight. The proportion of detackifier in the coating
may vary between 1 to 35% of the coating dry weight. The relative proportion of the pH
independent polymer may be varied depending on the release profile to be obtained (where
a more delayed release is generally obtained with a higher amount of pH independent filmforming
polymer is used and vice versoFurther, the amount of sodium alginate, plasticizer
and detackifier are varied to achieve a fine balance between these ingredients and prepare
suitable film coating composition.
The lag-period may also be modified to desired level by varying amount of coating applied
to the substrate. For example the lower concentration ofpolymer in the coating composition
reduces the time-lag; however, the lesser duration of time lag can be increased significantly
by increasing the total coating applied to the substrate, which may be measured in terms of
thecoating weight on the tablet. Similarly, the higher concentration of polymer results in
greater time lag and same canreduced by decreasing the coating weight gain on the tablet.
This finding gives flexibility to the formulator t o design a system with most optimized results
in terms of desired delaying action. An important aspect of the invention is that the delay in
release of active ingredient can be achieved without the use of any pore-forming agent.
The coating process may be as follows. The composition of the present invention may easily
be dispersed in water with the use of a propeller stirrer. The prepared suspension/solution
is then sprayed onto the substrate using standard coating machine and standard coating
parameters used for aqueous film coating process. The coating weight gain on the core
tablet may vary from 5% w/w t o anything up to 20% w/w depending on the desired delaying
action.
For instance, the inventive composition may be sprayed by Schlick™ spray gun having 0.8-
1.2 mm nozzle size and by adapting the following coating parameters, such as Inlet air
temperature in the range of 65-70 degree Celsius, Tablet bed temperature in the range of
30-45degree Celsius, suitable pump speed, pan speed, an atomizing air pressure in the
range of 1.4-3.0KG/cm sq. as per requirement of lot size to be coated.
The composition may be practiced as transparent, translucent, opaque or coloured by
adding suitable opacifier, colours and pigments. The composition may also be easily
modified by adding other excipients like sweeteners, flavours, other taste or flavor
enhancing agents t o improve its organoleptic properties.
The above principles may be employed to successfully coat a wide range of tablets having a
wide variety of active ingredients incorporated therein. For example, the composition of the
present invention may be used t o coat suitable dosage forms containing the active
pharmaceutical ingredient. Suitable active pharmaceutical ingredients include, but are not
limited to: adrenergic blocking agent; acetyl-choline-esterase inhibitor; analgesic or
antipyretics; angiotensin modulator; anthelmintic agents; anti-anxiety agent; antibacterial;
antibiotic; anticoagulant; anticonvulsant; antidepressant; antifungal; antihistamine;
antimalarial; antimicrobial agent; antipsychotic agent; Antiviral agents; blood glucose
lowering drug; calcium channel modulator; diuretic; erectile dysfunction; gastric acid
secretion inhibitor; histamine H2-receptor antagonist; inhibitor of steroid Type II 5[alpha]-
reductase including; lipid regulating agents; selective HI- receptor antagonist; vasodilator;
vitamins.
The composition of the present invention was found to be synergistic and optimum results
were obtained by using a combination of all components of the composition.
In another embodiment, the present invention provides a method for delaying the release
of an active ingredient into biological environment by a predetermined lag period,
comprising the steps of:
(i) providing active ingredient in a suitable dosage form and
(ii) coating the product of step (i) with the composition of the present invention.
ADVANTAGES
1. Present invention provides tailor-made composition for pre-defined release of active
ingredient.
2. Present invention also provides release modification based on polymer
concentration and relative coatingweight gain.
3. The present invention also provides flexibility in terms of compositions wherein the
time of delay in release of the active ingredient may be engineered as per the
requirement of the manufacturer.
The invention is not limited t o the specific embodiments described above but may bevaried
within broad limits by the skilled man.
EXAMPLES:
The following examples will further serve to provide details of the invention. However they
do not in any way limit the scope of the invention. All units and percentages in the examples
are by weight.
DISINTEGRATION TEST:
The disintegration tests of coated tablet performed as specified in IP (Indian
Pharmacopoeia) or USP (United States Pharmacopoeia). It is t o be understood that the
composition of the present invention may also be tested by other disintegration tests.
Indeed, various modifications of the described modes for carrying out the invention that are
apparent to those skilled in the art are intended to be within the scope of the present
invention.
EXAMPLE 1 :-
All Inventive composition ingredients are weighed as per table 2 and mixed in a standard
blender or mixer.
TABLE 2
The coating composition of the present invention is prepared as a ready t o use dry blend
and is reconstituted in purified water. Further composition as prepared is coated on
Creatine tablets having raw weight of 1400 mg Capsule shape, dimensions (length- 15 mm &
thickness 7 mm). Tablets were coated on Logica Progetti coating machine having Pellegrini
drum and spray gun type of Schlick ABC (0.8 mm). For instance, the inventive composition
may be sprayed by adapting the following coating parameters, such as Inlet air temperature
in the range of 65-70 degree Celsius, Tablet bed temperature in the range of 40-45 degree
Celsius, suitable pump speed, pan speed, an atomizing air pressure of 2.0 Bar or as per
requirement of lot size t o be coated.
Additionally other active ingredients are coated as per standard protocol. Upon testing
disintegration at pH 1.2 of coated oral substrate obtained from above composition
displayed following results at Table 2.1:-
TABLE 2.1
EXAMPLE 2
Inventive composition as prepared in example 1 is coated on Mint oil Soft-gel capsule having
fish oil weight of 750 mg, Almond shape dimensions (length- 11 mm & thickness 6 mm).
Tablets were coated on Logica Progetti coating machine having Pellegrini drum and spray
gun type of Schlick ABC (0.8 mm). For instance, the inventive composition may be sprayed
by adapting the following coating parameters, such as Inlet air temperature in the range of
65-70 degree Celsius, Tablet bed temperature in the range of 35-36 degree Celsius, suitable
pump speed, pan speed, an atomizing air pressure of 2.4 bar or as per requirement of lot
size t o be coated.
Additionally other active ingredients are coated as per standard protocol. Upon testing
disintegration at pH 1.2 of coated oral substrate obtained from above Soft-gel capsule
displayed following results:-
TABLE 3
EXAMPLE 3:
The active ingredient and optionally other ingredients are first blended in a mixer, and then
the solution or suspension of binder is sprayed onto this mix in a granulator. For example,
fluidized bed granulators can be used for this operation. An alternative process can be t o
use a conventional or high shear mixer to achieve granulation t o obtain granules. Granules
once dried can be mixed with the other excipients, especially with the lubricant, but also
with glidants and any other excipient suitable t o improve processing. The mixture of
granules (preferably with lubricant), and optionally glidant is pressed into tablets.
Alternatively, tablets containing the active ingredient can be obtained by standard
techniques, and are hereinafter referred as tablet cores.
Individual ingredients (with individual plasticizers) are weighed as per table 5 and mixed in a
standard blender or mixer.
TABLE 5
Ingredient Percentage by weight Weight in grams
Sodium Alginate 60 600
Triacetin/Di-ethyl 9.4 94
phthalate/CastorOil/Glycerine/
Polyethylene Glycol
Talc 14 140
Sodium methyl paraben 0.5 5
Sodium benzoate 0.1 1
Ti0 2 16 160
Total 100 1000
The coating composition of the present invention is prepared as a ready t o use dry blend
and is reconstituted in purified water.
These tablet cores are then coated with the coating composition of the invention t o achieve
a desired timed release of the active ingredient. For instance, the inventive composition
may be sprayed by adapting the following coating parameters, such as Inlet air temperature
in the range of 65-70 degree Celsius, Tablet bed temperature in the range of 40-45 degree
Celsius, suitable pump speed, pan speed, an atomizing air pressure in the range of 1.4-
3.0KG/cm sq. as per requirement of lot size to be coated.
When any of the composition of Example 1 was coated, different lag periods could be
predetermined by varying the weight of the composition. It is inferred that plasticizer acts
in a synergistic manner with the polymer.
EXAMPLE 4
The tablet cores with the active ingredient are prepared in a similar manner as described in
Example 3. Individual ingredients are weighed as per Table 6 and mixed in a standard
blender or mixer.
TABLE 6
Ingredient Percentage by weight Weight in grams
Sodium Alginate 60 600
Castor oil 4.4 44
Glycerine 5 50
Talc 14 140
Sodium methyl paraben 0.5 5
Sodium benzoate 0.1 1
Total 100 1000
The coating composition of the present invention is prepared as a ready t o use dry blend
and is reconstituted in purified water. The tablet cores are coated in a similar manner as
described in example 3.
Upon testing disintegration at pH 1.2 of coated oral substrate obtained from above^ablet
remain stable for 120 mins at 15 %weight gain.
EXAMPLE 5 The effect of polymer concentration
The tablet cores with the active ingredient are prepared in a similar manner as described in
Example 3. Individual ingredients are weighed as per Table 7 and mixed in a standard
blender or mixer.
TABLE 7
The coating composition of the present invention is prepared as a ready t o use dry blend
and is reconstituted in purified water. The tablet cores are coated in a similar manner as
described in example 3.
Upon testing disintegration at pH 1.2 of coated oral substrate obtained from above^tablet
remain stable for 120 mins at 12 %weight gain.
EXAMPLE 6
The tablet cores with the active ingredient are prepared in a similar manner as described in
example 3. Individual ingredients are weighed as per table 8 and mixed in a standard
blender or mixer.
TABLE 8
The coating composition of the present invention is prepared as a ready t o use dry blend
and is reconstituted in purified water. The tablet cores are coated in a similar manner as
described in example 3.
Upon testing disintegration at pH 1.2 of coated oral substrate obtained from above^ablet
remain stable for 120 mins at 18 %weight gain.
EXAMPLE 7
The tablet cores with the active ingredient are prepared in a similar manner as described in
example 3. Individual ingredients are weighed as per table 9 and mixed in a standard
blender or mixer.
TABLE 9
Ingredient Percentage by weight Weight in grams
Sodium Alginate 30 300
Plasticizer 9.4 94
Talc 28 280
Sodium methyl paraben 0.5 5
Sodium benzoate 0.1 1
Ti0 2 28 280
Total 100 1000
The coating composition of the present invention is prepared as a ready t o use dry blend
and is reconstituted in purified water. The tablet cores are coated in a similar manner as
described in example 3.
Upon testing disintegration at pH 1.2 of coated oral substrate obtained from above tablet
remain stable for 120 mins at 20 %coating weight gain.
Further the compositions of the present invention may also contain other pigments or
colors.
EXAMPLE 8
The tablet cores with the active ingredient are prepared in a similar manner as described in
example 3. Individual ingredients are weighed as per table 10 and mixed in a standard
blender or mixer.
TABLE 10
The coating composition of the present invention is prepared as a ready to use dry blend
and is reconstituted in purified water. The tablet cores are coated in a similar manner as
described in example 3. DT values were ranging from 24 to 120 minutes when the coating
weight gain was varied from 7-20%
EXAMPLE 9
The tablet cores with the active ingredient are prepared in a similar manner as described in
example 3. Individual ingredients are weighed as per table 11 and mixed in a standard
blender or mixer.
TABLE 11
The coating composition of the present invention is prepared as a ready t o use dry blend
and is reconstituted in purified water. The tablet cores are coated in a similar manner as
described in example 3.
Upon testing disintegration at pH 1.2 of coated oral substrate obtained from above tablet
remain stable for 20-100 minutes when the coating weight gain was varied from 7-15%.
EXAMPLE 10
The tablet cores with the active ingredient are prepared in a similar manner as described in
example 3. Individual ingredients are weighed as per table 12 and mixed in a standard
blender or mixer.
TABLE 12
Ingredient Percentage by weight Weight in grams
Sodium Alginate 60 600
Glycerin 6 60
Talc 13.5 135
Sorbic acid 0.5 5
Ti0 2 20 200
Total 100 1000
The coating composition of the present invention is prepared as a ready t o use dry blend
and is reconstituted in purified water. The tablet cores are coated in a similar manner as
described in example 3.
Upon testing disintegration at pH 1.2 of coated oral substrate obtained from above tablet
remain stable for 60 mins at 12 %weight gain.
Use of different diluents and fillers was studied by way of following examples;
EXAMPLE 11
The tablet cores with the active ingredient are prepared in a similar manner as described in
example 3. Individual ingredients are weighed as per table 13 and mixed in a standard
blender or mixer.
TABLE 13
Ingredient Percentage by weight Weight in grams
Sodium Alginate 50 500
Plasticizer 9.4 94
MCC PH 105 10 100
Talc 14 140
Sodium methyl paraben 0.5 5
Sodium benzoate 0.1 1
Ti0 2 16 160
Total 100 1000
The coating composition of the present invention is prepared as a ready t o use dry blend
and is reconstituted in purified water. The tablet cores are coated in a similar manner as
described in example 3.
Upon testing disintegration at pH 1.2 of coated oral substrate obtained from above, tablet
remains stable for 70 mins at 15 %weight gain.
EXAMPLE 12
The tablet cores with the active ingredient are prepared in a similar manner as described in
example 3. Individual ingredients are weighed as per table 14 and mixed in a standard
blender or mixer.
TABLE 14
The coating composition of the present invention is prepared as a ready to use dry blend
and is reconstituted in purified water. The tablet cores are coated in a similar manner as
described in example 3.
Upon testing disintegration at pH 1.2 of coated oral substrate obtained from above tablet
remain stable for 60 at 10% weight gain, and remain intact for 120 mins at 15 % weight
gain.
EXAMPLE 13
The tablet cores with the active ingredient are prepared in a similar manner as described in
example 3. Individual ingredients are weighed as per table 15 and mixed in a standard
blender or mixer.
TABLE 15
The coating composition of the present invention is prepared as a ready t o use dry blend
and is reconstituted in purified water. The tablet cores are coated in a similar manner as
described in example 3.
The coated oral substrate as obtained from above displayed a disintegration time 65 mins at
10 %weight gain and more than 120 mins at 15 %weight gain.
EXAMPLE 14
The tablet cores with the active ingredient are prepared in a similar manner as described in
example 3. Individual ingredients are weighed as per table 16 and mixed in a standard
blender or mixer.
TABLE 16
The coating composition of the present invention is prepared as a ready t o use dry blend
and is reconstituted in purified water. The tablet cores are coated in a similar manner as
described in example 3.
Upon testing disintegration at pH 1.2 of coated oral substrate obtained from above tablet
remain stable for 60 mins at 10 %weight gain and remain intact for 120 mins at 15 %weight
gain.
EXAMPLE 15
The tablet cores with the active ingredient are prepared in a similar manner as described in
example 3. Individual ingredients are weighed as per table 17 and mixed in a standard
blender or mixer.
TABLE 17
Ingredient Percentage by weight Weight in grams
Sodium Alginate 50 500
Plasticizer 9.4 94
Modified Starch 10 100
Talc 14 140
Sodium methyl paraben 0.5 5
Sodium benzoate 0.1 1
Ti0 2 16 160
Total 100 1000
The coating composition of the present invention is prepared as a ready t o use dry blend
and is reconstituted in purified water. The tablet cores are coated in a similar manner as
described in example 3.
Upon testing disintegration at pH 1.2 of coated oral substrate obtained from above L tablet
remain stable for 120 mins at 15 %weight gain
EXAMPLE 16
The tablet cores with the active ingredient are prepared in a similar manner as described in
example3. Individual ingredients are weighed as per table 18 and mixed in a standard
blender or mixer.
TABLE 18
The coating composition of the present invention is prepared as a ready t o use dry blend
and is reconstituted in purified water. The tablet cores are coated in a similar manner as
described in example 3.
Upon testing disintegration at pH 1.2 of coated oral substrate obtained from above tablet
remain stable for 40mins at 15% weight gain.
EXAMPLE 17
The tablet cores with the active ingredient are prepared in a similar manner as described in
example3. Individual ingredients are weighed as per table 19 and mixed in a standard
blender or mixer.
TABLE 19
The coating composition of the present invention is prepared as a ready to use dry blend
and is reconstituted in purified water. The tablet cores are coated in a similar manner as
described in example 3.
Upon testing disintegration at pH 1.2 of coated oral substrate obtained from above L tablet
remain stable for 120 mins at 15 %weight gain.
Further it was also observed that the incorporation of higher viscosity grade of Sodium
Alginate only affect the viscosity of the coating suspension and thereby affecting the
polymer carrying capacity of the suspension, however the same can also be used to delay
the drug release from the coated substrate.
Sodium alginate FMP is a higher viscosity grade (having viscosity of 15-20cps) whereas the
viscosity of Sodium- alginate used in other examples was less than 10 cps more preferably 5-
lOcps.
EXAMPLE 18
The tablet cores with the active ingredient are prepared in a similar manner as described in
example3. Individual ingredients are weighed as per table 20 and mixed in a standard
blender or mixer.
TABLE 20
The coating composition of the present invention is prepared as a ready t o use dry blend
and is reconstituted in a suitable solvent. The tablet cores are coated in a similar manner as
described in example 3.
Upon testing disintegration at pH 1.2 of coated oral substrate obtained from above tablet
remain stable for 120 mins at 15 % weight gain.
EXAMPLE 19
The tablet cores with the active ingredient are prepared in a similar manner as described in
example3. Individual ingredients are weighed as per table 21 and mixed in a standard
blender or mixer.
TABLE 21
Ingredient Percentage by weight Weight in grams
Sodium Alginate 60 600
Polyethylene Glycol 9.4 94
Talc 10 100
Sodium methyl paraben 0.5 5
Sodium benzoate 0.1 1
Stearic acid 2 20
Ti0 2 18 180
Total 100 1000
The coating composition of the present invention is prepared as a ready to use dry blend
and is reconstituted in purified water.
These tablet cores are then coated with the coating composition of the invention t o achieve
a desired timed release of the active ingredient. For instance, the inventive composition
may be sprayed by adapting the following coating parameters, such as Inlet air temperature
in the range of 65-70 degree Celsius, Tablet bed temperature in the range of 40-45 degree
Celsius, suitable pump speed, pan speed, an atomizing air pressure in the range of 1.4-
3.0KG/cm sq. as per requirement of lot size to be coated.
Upon testing disintegration at p 1.2 of coated oral substrate obtained from above 4 tablet
remain stable for 120mins at 15 % weight gain. It is to be understood that various
modifications and variations of the methods and compositions of the invention described
herein will be apparent to those skilled in the art without departing from the scope and
spirit of the invention. It may also be noted that the specific embodiments disclosed in the
examples do not in any way limit the scope of the present invention.
Indeed, various modifications of the described modes for carrying out the invention that are
apparent to those skilled in the art are intended t o be within the scope of the present
invention.
We claim,
1. A coating composition comprising, a pH independent polymer, a plasticizer, a
detackifier, and optionally, pharmaceutically acceptable additive wherein the
amount of pH independent polymer and weight gain of the tablet is relative t o a lag
period in disintegration of the coating.
2. The coating composition as claimed in claim 1, wherein the lag period is for a period
of 20-120 mins.
3. A coating composition as claimed in claim 1, wherein, the pH independent polymer is
sodium alginate.
4. The composition as claimed in claim 1, wherein the polymer is present in the range
from about 25% to about 85% by weight of the composition.
5. The composition as claimed in claim 1, wherein the plasticizer is selected from the
group consisting of polyethylene glycol, propylene glycol, glycerin, triacetin, triethyl
citrate, diethyl phthalate, dibutyl phthalate, liquid paraffin, castor oil, triglycerides,
coconut oil.
6. The composition as claimed in claim 1, wherein the plasticizer is present in the
range from about 3 to 15 %by weight of the composition.
7. The composition as claimed in claim 1, wherein the detackifier is selected from the
group consisting of talc, stearic acid, stearates of calcium, magnesium or zinc, kaolin,
glycerol mono sterate, preferably talc
8. The composition as claimed in claim 1, wherein the detackifier is present in the
range from about 3 to about 35% by weight of the composition.
9. The composition as claimed in claim 1, wherein the pharmaceutically acceptable
additives comprise a preservative, a coloring agent, an opacifier, a diluent, a
lubricant, a sweetener and a flavoring agent.
10. The composition as claimed in claim 1, wherein the preservative is selected from the
group consisting of sorbic acid, potassium sorbate, benzoic acid, sodium benzoate or
esters of hydroxybenzoic acid, parabens
11. The composition as claimed in claim 1, wherein the preservative is present in range
from about 0.1 t o about 2.0 %by weight of the composition.
12. The composition as claimed in claim 1, wherein the coloring agent is selected from
the group comprising colors and lakes approved by the FD & C, prefereably selected
from the group consisting of iron oxide colours, Lake colours, natural colours,
Candurin™ color and the like.
13. The composition as claimed in claim 1, wherein the opacifier is selected from the
group comprising titanium dioxide, zinc oxide, calcium carbonate, magnesium oxide.
14. The composition as claimed in claim 1, wherein the diluent is selected from the
group comprising Tri basic calcium phosphate, Micro-crystalline cellulose, calcium
phosphate, lactose.
15. The composition as claimed in claim 1, wherein the lubricant is selected from the
group comprising magnesium stearate, calcium stearate, zinc stearate, stearic acid,
mineral oil, and combinations thereof.
16. The composition as claimed in claim 1, wherein the sweetener is selected from the
group comprising glucose, fructose, sorbitol, aspartame, glycerol, saccharin, xylitol.
17. The composition as claimed in claim 1, wherein the flavoring agent is selected from
the group comprising powder, liquid, encapsulated flavors either natural or synthetic
origin.
18. The composition as claimed in claim 1, wherein the pH independent polymer,
preferably sodium alginate in the range 25 to 85% w/w, plasticizer in the range of 3-
15 % w/w, preferably 4-12% w/w, a detackifier in the range of 1-35% w/w, a
preservative in the range of 0.1-2% w/w and optionally a pigment in the range of 0.1-
35% w/w, an opacifier in the range of 0.1-30 % w/w and other excipients in the
range of 0.1-20 %w/w.
19. A method of making a dry coating composition comprising the steps of mixing a pH
independent polymer, adding a plasticizer, further adding a detackifier and mixing
until the combined mix is blended t o form the dry coating composition, wherein the
WO 2012/131476 PCT7IB2012/000625
H independent polymer, preferably sodium alginate in the range 25 to 85% w/w,
plasticizer in the range of 3-15 % w/w, preferably 4-12% w/w, a detackifier in the
range of 1-35% w/w, a preservative in the range of 0.1-2% w/w and optionally a
pigment in the range of 0.1-35% w/w, an opacifier in the range of 0.1-30 %w/w and
other excipients in the range of 0.1-20 %w/w
20. A method of coating using the composition as claimed in claim 1 comprising the
steps of
(i) providing active ingredient in a suitable dosage form and
(ii) coating the product of step (i) with the composition of claim-1 -
"A coating composition comprising, a pH independent polymer, a
plasticizer, a detackifier, and optionally, pharmaceutically acceptable
additive wherein the amount of pH independent polymer and weight
gain of the tablet is relative t o a lag period in disintegration of the
coating."
21. The method as claimed in claim 20, wherein the coating weight gain is from about 4
t o 50%, preferably 4 to 25% w/w.
22. A substrate coated with composition of claim 1.

Documents

Orders

Section Controller Decision Date

Application Documents

# Name Date
1 1627-MUMNP-2013-FORM 4 [23-04-2021(online)].pdf 2021-04-23
1 1627-MUMNP-2013-FORM PCT-ISA-237(18-10-2013).pdf 2013-10-18
2 1627-MUMNP-2013-FORM PCT-IB-326(18-10-2013).pdf 2013-10-18
2 1627-MUMNP-2013-ORIGINAL UR 6(1A) FORM 26-130919.pdf 2019-11-13
3 1627-MUMNP-2013-Written submissions and relevant documents (MANDATORY) [09-10-2019(online)].pdf 2019-10-09
3 1627-MUMNP-2013-FORM 26(18-10-2013).pdf 2013-10-18
4 1627-MUMNP-2013-HearingNoticeLetter23-09-2019.pdf 2019-09-23
4 1627-MUMNP-2013-FORM 1(18-10-2013).pdf 2013-10-18
5 1627-MUMNP-2013-FORM-26 [10-09-2019(online)].pdf 2019-09-10
5 1627-MUMNP-2013-CORRESPONDENCE(18-10-2013).pdf 2013-10-18
6 enterpreneurs memorandum acknowledgement.pdf ONLINE 2018-08-11
6 1627-MUMNP-2013-Correspondence to notify the Controller (Mandatory) [04-07-2019(online)].pdf 2019-07-04
7 enterpreneurs memorandum acknowledgement.pdf 2018-08-11
7 1627-MUMNP-2013-CLAIMS [11-09-2018(online)].pdf 2018-09-11
8 1627-MUMNP-2013.pdf 2018-08-11
8 1627-MUMNP-2013-COMPLETE SPECIFICATION [11-09-2018(online)].pdf 2018-09-11
9 1627-MUMNP-2013-FER_SER_REPLY [11-09-2018(online)].pdf 2018-09-11
9 1627-MUMNP-2013-PCT REQUEST.pdf 2018-08-11
10 1627-MUMNP-2013-CLAIMS.pdf 2018-08-11
10 1627-MUMNP-2013-FORM PCT-ISA-210.pdf 2018-08-11
11 1627-MUMNP-2013-CORRESPONDENCE.pdf 2018-08-11
11 1627-MUMNP-2013-FORM PCT-IB-308.pdf 2018-08-11
12 1627-MUMNP-2013-FER.pdf 2018-08-11
12 1627-MUMNP-2013-FORM PCT-IB-304.pdf 2018-08-11
13 1627-MUMNP-2013-FORM 1.pdf 2018-08-11
13 1627-MUMNP-2013-FORM 5.pdf 2018-08-11
14 1627-MUMNP-2013-FORM 2(TITLE PAGE).pdf 2018-08-11
14 1627-MUMNP-2013-FORM 3.pdf 2018-08-11
15 1627-MUMNP-2013-FORM 2(TITLE PAGE).pdf 2018-08-11
15 1627-MUMNP-2013-FORM 3.pdf 2018-08-11
16 1627-MUMNP-2013-FORM 1.pdf 2018-08-11
16 1627-MUMNP-2013-FORM 5.pdf 2018-08-11
17 1627-MUMNP-2013-FORM PCT-IB-304.pdf 2018-08-11
17 1627-MUMNP-2013-FER.pdf 2018-08-11
18 1627-MUMNP-2013-CORRESPONDENCE.pdf 2018-08-11
18 1627-MUMNP-2013-FORM PCT-IB-308.pdf 2018-08-11
19 1627-MUMNP-2013-CLAIMS.pdf 2018-08-11
19 1627-MUMNP-2013-FORM PCT-ISA-210.pdf 2018-08-11
20 1627-MUMNP-2013-FER_SER_REPLY [11-09-2018(online)].pdf 2018-09-11
20 1627-MUMNP-2013-PCT REQUEST.pdf 2018-08-11
21 1627-MUMNP-2013-COMPLETE SPECIFICATION [11-09-2018(online)].pdf 2018-09-11
21 1627-MUMNP-2013.pdf 2018-08-11
22 1627-MUMNP-2013-CLAIMS [11-09-2018(online)].pdf 2018-09-11
22 enterpreneurs memorandum acknowledgement.pdf 2018-08-11
23 1627-MUMNP-2013-Correspondence to notify the Controller (Mandatory) [04-07-2019(online)].pdf 2019-07-04
23 enterpreneurs memorandum acknowledgement.pdf ONLINE 2018-08-11
24 1627-MUMNP-2013-CORRESPONDENCE(18-10-2013).pdf 2013-10-18
24 1627-MUMNP-2013-FORM-26 [10-09-2019(online)].pdf 2019-09-10
25 1627-MUMNP-2013-HearingNoticeLetter23-09-2019.pdf 2019-09-23
25 1627-MUMNP-2013-FORM 1(18-10-2013).pdf 2013-10-18
26 1627-MUMNP-2013-Written submissions and relevant documents (MANDATORY) [09-10-2019(online)].pdf 2019-10-09
26 1627-MUMNP-2013-FORM 26(18-10-2013).pdf 2013-10-18
27 1627-MUMNP-2013-ORIGINAL UR 6(1A) FORM 26-130919.pdf 2019-11-13
27 1627-MUMNP-2013-FORM PCT-IB-326(18-10-2013).pdf 2013-10-18
28 1627-MUMNP-2013-FORM PCT-ISA-237(18-10-2013).pdf 2013-10-18
28 1627-MUMNP-2013-FORM 4 [23-04-2021(online)].pdf 2021-04-23

Search Strategy

1 1627MUMNP2013_07-03-2018.pdf